BAL Pharma Ltd.
NSE: BALPHARMA · Pharmaceuticals · sector
₹79.10NSE close 2026-10-26
Key numbers
Market cap₹126 cr
Price₹79.10
52w high / low₹125 / ₹60
P/E17.4xSector median 27.9x
P/B1.5xSector median 2.9x
Book value₹51.6
Dividend yield1.52%Sector median 0.48%
ROE9.0%Sector median 11.7%
ROCE10.0%Sector median 12.3%
OPM10.1%Sector median 14.0%
Debt / equity1.94xSector median 0.16x
EV/EBITDA8.3xSector median 18.6x
Interest cover1.4x
Current ratio1.05x
Sales growth 3y+0.8%Sector median +9.6%
Profit growth 3y+33.9%Sector median +13.3%
PEG0.52x
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹6 cr vs borrowings ₹160 cr (FY26): borrowings are higher by ₹154 cr.
- Borrowings rose in each of the last 3 years (₹131 cr → ₹160 cr).
- Operating profit covered interest 1.4x in the last 12 months.
- No promoter shares are pledged.
- Operating cash flow was below net profit in 0 of the last 5 years.
- Revenue was higher than a year earlier in 4 of the last 4 quarters.
- Other income was 23% of net profit in the last 12 months.
- Dividend paid in 5 of the last 5 financial years.
- Price ₹79.10 on 2026-10-26: -36.5% from the 52-week high, +31.8% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹136.61 · low ₹64.87
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 74 | 73 | 82 | 66 | 74 | 88 | 84 | 89 |
| EBITDA | 8 | 8 | 8 | 6 | 6 | 10 | 11 | 8 |
| OPM % | 10.4% | 10.6% | 9.3% | 9.2% | 7.7% | 10.9% | 12.6% | 9.0% |
| Other income | -0 | 1 | 1 | 1 | 1 | 0 | -0 | 0 |
| Net profit | 1 | 0 | 7 | 0 | 1 | 2 | 4 | 1 |
| EPS (₹) | 0.65 | 0.33 | 3.40 | 0.13 | 0.45 | 1.12 | 2.26 | 0.71 |
| Revenue YoY | +0.4% | +19.9% | +2.7% | +34.5% | ||||
| Profit YoY | -31.7% | +270.8% | -46.7% | +433.3% |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 281 | 304 | 339 | 303 | 312 | 334 |
| EBITDA | 23 | 25 | 32 | 30 | 32 | 34 |
| Net profit | 6 | 3 | 7 | 7 | 6 | 7 |
| EPS (₹) | 3.79 | 1.67 | 4.94 | 4.56 | 3.95 | 4.54 |
| Revenue growth | +8.2% | +11.5% | -10.7% | +2.8% | +13.5% | |
| Profit growth | -53.3% | +182.1% | -2.3% | -13.0% | -14.9% | |
| Dividend / share (₹) | 1.00 | 1.00 | 1.00 | 1.20 | 1.20 |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +0.8% | +4.5% | +13.5% |
| Net profit | +33.9% | +5.8% | -14.9% |
| EPS | +33.2% | +3.4% | – |
| Share price | – | -16.9% (2y) | +4.0% |
Balance sheet
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Shareholders' equity | – | 64 | 69 | 77 | 82 |
| Borrowings | – | 131 | 140 | 150 | 160 |
| Cash & equivalents | – | 8 | 20 | 11 | 6 |
| Total assets | – | 313 | 320 | 336 | 376 |
| Fixed assets | – | 62 | 62 | 71 | 77 |
| Capital work in progress | – | 0 | 0 | 3 | 7 |
| Investments | – | 0 | 0 | 0 | 0 |
| Receivables | – | 94 | 100 | 92 | 94 |
| Inventory | – | 98 | 88 | 103 | 116 |
| Payables | – | 79 | 78 | 82 | 89 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | 32 | 23 | 329 | 21 | 31 |
| Cash from investing | 11 | 18 | 0 | -18 | -21 |
| Cash from financing | 1 | 0 | 35 | 0 | -10 |
| Capex | 0 | 0 | 0 | 0 | 19 |
| Free cash flow | 32 | 23 | 329 | 21 | 12 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ROE % | – | 4.1% | 10.7% | 9.3% | 7.6% |
| ROCE % | – | 8.7% | 11.6% | 9.7% | 9.4% |
| Debtor days | – | 113 | 107 | 111 | 110 |
| Inventory days | – | 207 | 167 | 238 | 269 |
| Payable days | – | 167 | 149 | 189 | 206 |
| Cash conversion cycle (days) | – | 153 | 125 | 160 | 173 |
| Working capital days | – | 23 | 33 | 19 | 15 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 50.86% |
| FIIs | 0.28% |
| Public (non-institutions) | 48.87% |
| Quarter | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 50.86% | 50.86% | 50.86% | 50.86% | 50.86% | 50.86% | 50.86% | 50.86% |
| Promoter group | % |
|---|---|
| Shailesh Siroya | 17.24% |
| Micro Labs Limited | 12.64% |
| Anita Siroya | 6.59% |
| Anand Surana | 3.30% |
| Chandraprakash Dheerajmal Siroya | 3.06% |
| Dilip Surana | 2.98% |
| Archana Surana | 1.79% |
| Monica Surana | 1.13% |
| Dilip Surana (HUF) | 1.07% |
| Anita Chandraprakash Siroya | 0.77% |
| Jivi Dheerajmal Siroya | 0.29% |
| Shrenik Siroya | 0.00% |
| Public holders above 1% | % |
|---|---|
| Ram Keshav Murthy | 3.31% |
| Prakash Chandra Jain | 2.89% |
| Naresh D P | 1.88% |
| Shreya Mardia | 1.88% |
| Asha Tapidas Dodhia | 1.84% |
| Gautam Chand Mehta | 1.16% |
15,241 shareholders. Pledged: 0.00% of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| BALPHARMA | ₹126 cr | 17.4x | 1.5x | 9.0% | 10.0% | 10.1% | +0.8% | 1.52% |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2026-09-17 | Dividend | Dividend - Rs 1.20 Per Share |
| 2025-09-18 | Dividend | Dividend - Rs 1.20 Per Share |
| 2024-09-17 | Dividend | Annual General Me0etingdividend - Rs 1.2 Per Share |
| 2023-09-18 | Dividend | Annual General Meeting/Dividend - Re 1 Per Share |
| 2022-09-13 | Dividend | Annual General Meetingdividend - Re 1 Per Share |
| 2021-09-16 | Dividend | Annual General Meeting/Dividend - Re 1 Per Share |
| 2020-09-17 | Other | Annual General Meeting |
| 2019-09-17 | Dividend | Annual General Meeting/Dividend - Re 1 Per Share |
| 2018-09-14 | Dividend | Annual General Meeting/Dividend Re 1 Per Share |
| 2017-09-14 | Dividend | Annual General Meeting/Dividend - Re 1/- Per Share |
| 2016-09-15 | Dividend | Annual General Meeting/Dividend Re 1/- Per Share |
| 2015-09-15 | Dividend | Annual General Meeting/ Dividend - Re 1/- Per Share |
| 2014-09-12 | Dividend | Annual General Meeting / Dividend - Re 1/- Per Share |
| 2013-09-12 | Dividend | Annual General Meeting / Dividend - Re 0.75/- Per Share |
| 2012-09-17 | Other | Annual General Meeting |
| 2011-09-19 | Other | Annual General Meeting |
| 2010-09-23 | Other | Annual General Meeting |
| 2009-09-17 | Dividend | Dividend-Re.0.75 Pr Share |
| 2008-09-09 | Dividend | Agm/Dividend - 10% |
| 2007-09-07 | Dividend | Agm/Dividend-7.5% |
Documents
- Annual report FY26
- Annual report FY25
- Annual report FY24
- Annual report FY23
- Annual report FY22
- Announcements NSE filings
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | BALPHARMA |
| BSE code | 524824 |
| ISIN | INE083D01012 |
| Face value | ₹10.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-23 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.